Please assess the completion status of the following clinical trial:

Trial Title: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Pyuria~* Have a pretreatment baseline urine culture obtained within 36 hours before the start of administration of the first dose of study drug~* Clinical signs and/or symptoms of acute pyelonephritis or complicated urinary tract infection~* Normal renal function or moderate renal impairment~Key Exclusion Criteria:~* Confirmed fungal urinary tract infection at the time of randomization~* Known urinary tract infection or colonization with Gram-positive pathogens~* Current cUTI or AP is known to be caused by a pathogen resistant to meropenem~* Female participants of childbearing potential if they are known to be pregnant or have a positive pregnancy test at screening, breastfeeding, or unable or unwilling to use a highly effective method of birth control during the study and for at least 30 days following the last dose of study medication~* Any rapidly progressing disease or immediately life-threatening illness~* Documented presence of immunodeficiency or an immunocompromised condition~* Documented or known history of otologic surgery or disease including use of hearing aid, head injury leading to otologic damage, Ménière's disease, tumor of the head, neck, or auditory system, perilymphatic fistula, or autoimmune disease of the inner ear, or family history of hearing loss (excluding age-related hearing loss \[onset after age of 65 years\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plazomicin (Type: EXPERIMENTAL): Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
- Meropenem (Type: ACTIVE_COMPARATOR): Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).

Based on this trial design, predict the completion outcome and termination type (if applicable).